Alector, Inc.

Alector, Inc.

ALECNYSE / NASDAQHealthcareSmall cap

$2.34+$0.04 (+1.5%)

Last close · Data as of Nov 20, 2026

Market cap
$201.0M
Revenue
$21.0M
Net margin
-679.3%
ROCE
-386.7%

+94.6% over the last year

Alector, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
+18.5%
3M
+3.3%
6M
+10.1%
1Y
+94.6%
5Y
-89.1%

52-week range

Day change +$0.04 (+1.5%) from $2.30 to $2.34 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in ALEC, bought on each weekday since 2021.

News & filings

What Alector filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernThe company made a net loss of 143 million US dollars in fiscal 2025.

Strengths (1)

  • Cash on the balance sheet is more than the company's market value.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Alector, Inc., a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States.

Read moreShow less

Alector, Inc., a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States. Its pipeline includes Nivisnebart, an investigational human recombinant monoclonal antibody for treating prevalent neurodegenerative diseases; AL137, an anti-amyloid beta antibody paired in preclinical development for the potential treatment of Alzheimer's disease; and AL050, a GCase enzyme replacement therapy in preclinical development for the potential treatment of Parkinson's disease and Lewy body dementia in patients having GBA1 gene mutations. The company also develops its preclinical and research pipeline comprising AL064, a tau siRNA for Alzheimer's disease and other tauopathies; ADP062-ABC, an alpha-synuclein siRNA for Parkinson's disease; and ADP065-ABC, an NLRP3 siRNA for neurodegenerative conditions. It has a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of progranulin-elevating monoclonal antibodies, including Latozinemab and Nivisnebart. The company was founded in 2013 and is headquartered in South San Francisco, California.

Sector
Healthcare
Shares outstanding
110.4M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$201.0M
P/B
6.6x
EV / Sales
-0.9x
P/S
9.6x
52-week high
$2.72
52-week low
$1.14

Profitability

Operating margin
-741.5%
Net margin
-679.3%
EBITDA margin
-695.6%
ROE
-466.3%
ROCE
-386.7%
ROIC
-11411.6%
ROA
-48.7%
Asset turnover
0.07

Growth

Revenue
$21.0M
Revenue growth, 1Y
-79.1%
Revenue CAGR, 3Y
-46.0%
Net profit growth, 1Y
20.1%
Free cash flow
-$184.1M

Solvency

Current ratio
3.83
Debt / Equity
1.18
Debt / Assets
0.12
CFO / Net profit
1.29
Cash / Market cap
127.4%

Where the revenue went

FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.

LineFY2025
Revenue$21.0M
Gross profit$21.0M
Operating expenses$177.0M
Research and development$123.1M
Selling, general and administrative$54.0M
Operating income-$156.0M
Interest and other$13.3M
Pretax income-$142.8M
Tax and other$170.0k
Net income-$142.9M

Revenue and net profit

Revenue fell 79.1% in FY2025; net profit is the dashed line.

Alector, Inc. revenue and net profit by fiscal year
Alector, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$133.6M-$133.3M
FY2023$97.1M-$130.4M
FY2024$100.6M-$119.0M
FY2025$21.0M-$142.9M

Cash flows

FY2025: -$184.0M from operations, -$184.1M free after investment (dashed).

Alector, Inc. operating and free cash flow by fiscal year
Alector, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022-$20.3M-$24.4M
FY2023-$184.2M-$186.5M
FY2024-$229.9M-$231.2M
FY2025-$184.0M-$184.1M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$21.0M-79.1%1Y
EBITDA
-$146.3M
Net profit
-$142.9M
Cash from operations
-$184.0M
Free cash flow
-$184.1M
Revenue CAGR, 3Y
-46.0%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$21.0M-$146.3M-$142.9M-$184.1M-466.3%-79.1%+20.1%

Monthly returns

Month-by-month returns of ALEC across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$293.2M
Liabilities$262.6M
Equity$30.6M
Paid-in capital$1.0B
Retained earnings-$972.1M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; ALEC highlighted.

P/E against peers

Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.

EV / Sales, for the companies without earnings

  1. Alector, Inc. (this company)-0.9x

Not shown (no positive earnings and no EV / Sales): Nkarta, Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Alector, Inc.ALECthis company$201.0M—6.6x-466.3%—
Accendra Health, Inc.ACH$202.9M-0.2x-0.4x238.8%9.3x
Sanara MedTech Inc.SMTI$202.7M-5.4x34.1x-632.5%22.7x
TriSalus Life Sciences, Inc.TLSI$202.7M-5.2x-6.0x115.8%-6.6x
Embecta Corp.EMBC$202.3M2.1x-0.3x-14.6%4.9x
Nkarta, Inc.NKTX$198.2M—0.6x-33.3%—
Anika Therapeutics, Inc.ANIK$196.8M-18.1x1.4x-7.6%-31.1x
Lucid Diagnostics Inc.LUCD$194.6M—17.8x-645.1%—
Cartesian Therapeutics, Inc.RNAC$192.4M-1.5x-1.5x103.2%-1.0x
Peer median—-3.3x0.2x-11.1%2.0x

Year-to-date ROI

ALEC since 1 January, against earlier years.

Historical volatility

ALEC's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Alector, Inc. operating margin by fiscal year
Alector, Inc. operating margin by fiscal year
DateOperating margin
FY2022-103.2%
FY2023-156.3%
FY2024-144.2%
FY2025-741.5%
LineFY2025
Operating expensesOperating Expense$177.1M
Research and developmentResearch And Development$123.1M
Total expensesTotal Expenses$177.1M
Pretax incomePretax Income-$142.8M

Learn while you research

Academy chapters picked for Alector, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  3. 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  4. 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  5. 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →